Clinical Trials Directory

Trials / Completed

CompletedNCT02224274

Antiplatelet Therapy After Cardiac Arrest

Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
57 (actual)
Sponsor
University Medical Centre Ljubljana · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients. The reasons for this are probably slower gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take action. Since ticagrelor has faster intestinal absorption and no need for liver metabolism we expect its effect to be good even in patients with therapeutic hypothermia after cardiac arrest. Patients treated with therapeutic hypothermia after cardiac arrest and percutaneous coronary intervention will be randomised into two groups. One will be treated with ASA and clopidogrel and the other with ASA and ticagrelor. Blood samples will be collected before and 2, 4, 12, 22 and 48 hours after P2Y12 inhibitor administration. Platelet function will be measured by VerifyNow P2Y12 assay and by Multiplate ADPTest. Differences between the groups will be analysed. Hypothesis: Antiplatelet therapy with ticagrelor is more effective than therapy with clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia and percutaneous coronary intervention (PCI).

Conditions

Interventions

TypeNameDescription
DRUGClopidogrel
DRUGTicagrelor

Timeline

Start date
2014-08-01
Primary completion
2016-06-01
Completion
2016-06-01
First posted
2014-08-25
Last updated
2019-02-27
Results posted
2019-02-27

Locations

1 site across 1 country: Slovenia

Source: ClinicalTrials.gov record NCT02224274. Inclusion in this directory is not an endorsement.